CryoLife, Inc. (CRY) Given Average Recommendation of “Hold” by Analysts

Shares of CryoLife, Inc. (NYSE:CRY) have received a consensus recommendation of “Hold” from the five analysts that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation and three have issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $22.33.

CRY has been the topic of a number of research reports. Northland Securities reissued a “buy” rating and issued a $23.50 target price on shares of CryoLife in a research note on Friday, April 28th. BidaskClub lowered shares of CryoLife from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Finally, Zacks Investment Research lowered shares of CryoLife from a “buy” rating to a “sell” rating in a research note on Wednesday, August 2nd.

TRADEMARK VIOLATION NOTICE: “CryoLife, Inc. (CRY) Given Average Recommendation of “Hold” by Analysts” was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://www.com-unik.info/2017/08/19/cryolife-inc-cry-given-average-rating-of-buy-by-brokerages-updated-updated-updated.html.

In other news, VP Amy Horton sold 9,577 shares of CryoLife stock in a transaction that occurred on Tuesday, June 27th. The shares were sold at an average price of $20.00, for a total transaction of $191,540.00. Following the sale, the vice president now owns 112,282 shares of the company’s stock, valued at approximately $2,245,640. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 6.00% of the stock is currently owned by insiders.

Several hedge funds have recently added to or reduced their stakes in the stock. Louisiana State Employees Retirement System raised its stake in CryoLife by 0.9% in the second quarter. Louisiana State Employees Retirement System now owns 11,100 shares of the medical equipment provider’s stock valued at $221,000 after buying an additional 100 shares during the last quarter. Municipal Employees Retirement System of Michigan raised its stake in CryoLife by 3.2% in the first quarter. Municipal Employees Retirement System of Michigan now owns 6,150 shares of the medical equipment provider’s stock valued at $102,000 after buying an additional 190 shares during the last quarter. Arizona State Retirement System raised its stake in CryoLife by 1.4% in the first quarter. Arizona State Retirement System now owns 14,054 shares of the medical equipment provider’s stock valued at $234,000 after buying an additional 200 shares during the last quarter. Creative Planning raised its stake in CryoLife by 3.0% in the second quarter. Creative Planning now owns 6,806 shares of the medical equipment provider’s stock valued at $136,000 after buying an additional 200 shares during the last quarter. Finally, Wells Fargo & Company MN raised its stake in CryoLife by 0.9% in the second quarter. Wells Fargo & Company MN now owns 31,313 shares of the medical equipment provider’s stock valued at $624,000 after buying an additional 271 shares during the last quarter. 68.13% of the stock is currently owned by hedge funds and other institutional investors.

CryoLife (NYSE CRY) traded up 1.09% during midday trading on Monday, hitting $18.55. The company had a trading volume of 27,832 shares. The company has a 50 day moving average price of $19.33 and a 200 day moving average price of $17.96. CryoLife has a 1-year low of $14.03 and a 1-year high of $20.30. The firm has a market capitalization of $620.42 million, a P/E ratio of 56.21 and a beta of 0.97.

CryoLife (NYSE:CRY) last released its earnings results on Monday, July 24th. The medical equipment provider reported $0.12 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.10 by $0.02. CryoLife had a net margin of 6.16% and a return on equity of 7.41%. The business had revenue of $47.80 million for the quarter, compared to analyst estimates of $47.02 million. During the same period last year, the company posted $0.13 EPS. The business’s revenue was up 1.5% on a year-over-year basis. Equities research analysts forecast that CryoLife will post $0.43 earnings per share for the current fiscal year.

CryoLife Company Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

What are top analysts saying about CryoLife Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CryoLife Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit